Drug Type Small molecule drug |
Synonyms DWP 212525, DWP-212525, DWP212525 |
Target |
Action inhibitors |
Mechanism BTK inhibitors(Tyrosine-protein kinase BTK inhibitors), JAK3 inhibitors(Tyrosine-protein kinase JAK3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Autoimmune Diseases | Phase 1 | United States | 10 Dec 2024 | |
| COVID-19 | Preclinical | South Korea | - | |
| Inflammatory Bowel Diseases | Preclinical | South Korea | - | |
| Pemphigus | Preclinical | South Korea | - | |
| Rheumatoid Arthritis | Preclinical | South Korea | - | |
| Systemic Lupus Erythematosus | Preclinical | South Korea | - |





